Novo Nordisk sets 2030 targets as GLP-1 rivals close in on Wegovy and Ozempic
The plan leans on pipeline drugs CagriSema and zenagamtide to diversify the business, with late stage trial results as the next test.
Recap by typeshit. Full story at Yahoo Finance.